insights_auto
Why is RARE up ၂.၆၉%?
Dive Deeperchevron_right
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
၁၅.၂၉ US$
arrow_upward
+၂.၆၉%(+၀.၄၀) 1D
၁၅.၂၉ US$
၀.၀၀% (၀.၀၀)
bedtimeAfter hours
Closed: အောက် ၈, GMT-၄ ၁၆:၀၀:၀၀ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RARE...
Open
၁၄.၇၉ US$
High
၁၅.၅၂ US$
Low
၁၄.၄၃ US$
Mkt. cap
၁၅၀.၇၄ ဋေ
Avg. vol.
၅.၈၉ သန်း
Volume
၅.၃၉ သန်း
52-wk high
၃၉.၈၉ US$
52-wk low
၁၂.၇၃ US$
EPS
-၅.၈၄ US$
Beta
၀.၃၅
Shares outstanding
၉.၈၆ ကုဋေ
No. of employees
၁ ထောင်
Open
၁၄.၇၉ US$
High
၁၅.၅၂ US$
Low
၁၄.၄၃ US$
Mkt. cap
၁၅၀.၇၄ ဋေ
Avg. vol.
၅.၈၉ သန်း
Volume
၅.၃၉ သန်း
52-wk high
၃၉.၈၉ US$
52-wk low
၁၂.၇၃ US$
EPS
-၅.၈၄ US$
Beta
၀.၃၅
Shares outstanding
၉.၈၆ ကုဋေ
No. of employees
၁ ထောင်
News stories
From web sources and news partners
Zacks
·
ပြီးခဲ့သည့် ၅ နာရီ
Ultragenyx to Sell Rare Pediatric Disease PRV for $210M to Boost Cash
Pharmaceutical Executive
·
ပြီးခဲ့သည့် ၅ နာရီ
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
Investing.com
·
ပြီးခဲ့သည့် ၈ နာရီ
H.C. Wainwright reiterates Ultragenyx stock rating on PRV sale
Pluang
·
ပြီးခဲ့သည့် ၁ ရက်
Ultragenyx shares rise 3.2% after selling FDA p...
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees၁.၃၇ ထောင်
Founded၂၀၁၀
HeadquartersNovato, ကယ်လီဖိုးနီးယားပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websiteultragenyx.com